145 related articles for article (PubMed ID: 28385778)
1. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
Scott EC; Maziarz RT; Spurgeon SE; Medvedova E; Gajewski J; Reasor-Heard S; Park B; Kratz A; Thomas GV; Loriaux M; Cascio M; Podolak J; Gordon M; Botelho J; Stadtmauer E; Amaravadi R; Vogl DT
Haematologica; 2017 Jul; 102(7):e261-e265. PubMed ID: 28385778
[No Abstract] [Full Text] [Related]
2. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Vogl DT; Stadtmauer EA; Tan KS; Heitjan DF; Davis LE; Pontiggia L; Rangwala R; Piao S; Chang YC; Scott EC; Paul TM; Nichols CW; Porter DL; Kaplan J; Mallon G; Bradner JE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1380-90. PubMed ID: 24991834
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Expression of mTOR in Multiple Myeloma: Retrospective Analysis of 31 Cases, a Clinicopathological Study.
Stockwin W; Johnson P; Vajpayee N
Ann Clin Lab Sci; 2016; 46(2):125-31. PubMed ID: 27098617
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
6. Clarithromycin attenuates autophagy in myeloma cells.
Nakamura M; Kikukawa Y; Takeya M; Mitsuya H; Hata H
Int J Oncol; 2010 Oct; 37(4):815-20. PubMed ID: 20811702
[TBL] [Abstract][Full Text] [Related]
7. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
8. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
9. The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.
Leisching GR; Loos B; Botha MH; Engelbrecht AM
Toxicology; 2015 Sep; 335():72-8. PubMed ID: 26201060
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
Zhang H; Chen J; Zeng Z; Que W; Zhou L
Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
[TBL] [Abstract][Full Text] [Related]
11. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
Tsai JP; Lee CH; Ying TH; Lin CL; Lin CL; Hsueh JT; Hsieh YH
Oncotarget; 2015 Oct; 6(30):28851-66. PubMed ID: 26311737
[TBL] [Abstract][Full Text] [Related]
12. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application.
Aronson LI; Davenport EL; Mirabella F; Morgan GJ; Davies FE
Leukemia; 2013 Dec; 27(12):2397-403. PubMed ID: 23670295
[No Abstract] [Full Text] [Related]
13. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
[TBL] [Abstract][Full Text] [Related]
15. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
16. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of survivin in bone marrow cells of multiple myeloma patients].
Li J; Zhao Y; Zhang DB; Huang BH
Ai Zheng; 2005 Dec; 24(12):1522-6. PubMed ID: 16351806
[TBL] [Abstract][Full Text] [Related]
18. Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity.
Townsend KN; Hughson LR; Schlie K; Poon VI; Westerback A; Lum JJ
Immunol Rev; 2012 Sep; 249(1):176-94. PubMed ID: 22889222
[TBL] [Abstract][Full Text] [Related]
19. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy.
Pan Y; Gao Y; Chen L; Gao G; Dong H; Yang Y; Dong B; Chen X
Clin Cancer Res; 2011 May; 17(10):3248-58. PubMed ID: 21288924
[TBL] [Abstract][Full Text] [Related]
20. Geraniol induces cooperative interaction of apoptosis and autophagy to elicit cell death in PC-3 prostate cancer cells.
Kim SH; Park EJ; Lee CR; Chun JN; Cho NH; Kim IG; Lee S; Kim TW; Park HH; So I; Jeon JH
Int J Oncol; 2012 May; 40(5):1683-90. PubMed ID: 22200837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
